Curevac announces dosing of first participant in combined phase 1/2 study of multivalent, modified influenza vaccine candidates developed in collaboration with gsk

Initial phase 1 part started with multivalent modified mrna influenza vaccine candidates candidates developed in collaboration with gsk within broad infectious disease vaccine program encode for antigens covering four who-recommended flu strains tÜbingen, germany and boston, ma / accesswire / may 8, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that the first participant was dosed in the phase 1 part of a combined phase 1/2 study of multivalent, modified mrna seasonal flu vaccine candidates, developed in collaboration with gsk.
CVAC Ratings Summary
CVAC Quant Ranking